Treatment options depend on the type of tumor and on its size: * Prolactinomas are most often treated with cabergoline or quinagolide (both dopamine agonists), which decrease tumor size as well as alleviates symptoms, followed by serial imaging to detect any increase in size. Treatment, where the tumor is large, can be with radiation therapy, proton therapy or surgery, and patients generally respond well. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment. * Somatotrophic adenomas respond to octreotide or lanreotide, which are long-acting somatostatin analogs. These somatostatin receptor analogs inhibit secretion of growth hormone. They were found to be about 50-55% effective in reducing tumor mass and reducing growth hormone and insulin like growth factor 1 (IGF-1) levels in studies. The growth hormone receptor antagonist pegvisomant is also used in the treatment of somatotrophic adenomas. Pegvisomant blocks the action of growth hormone. It can either be used as monotherapy or combined with a somatostatin analog. * Surgery is a common treatment for<unk>  tumors. The normal approach is trans-sphenoidal adenectomy, which usually can remove the tumor without affecting the brain or optic nerves. * Radiation is also used to treat<unk> s. Examples include external beam or proton beam radiation therapy or stereotactic radiosurgery. External radiation of<unk> s can arrest tumor growth for several years but<unk>  failure develops within 10 years in most patients necessitating lifelong hormone replacement. Radiation therapy for<unk> s is associated with a 4 fold increase in mortality due to cerebrovascular disease.
Pituitary adenoma
Adrenocortical adenoma
Metanephric adenoma
Thyroid adenoma
Parathyroid adenoma
Hürthle cell adenoma
Nephrogenic adenoma
Pituitary disease